Skip to main content

Hls Therapeutics Inc(HLS-T)
TSX

Today's Change
Real-Time Last Update
Day Low4.64
Day High4.65
Open:4.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics Announces Fiscal 2025 Financial Results
Newswire.ca
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease
Newswire.ca
HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call
GlobeNewswire
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Newswire.ca
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Newswire.ca
HLS Therapeutics Announces Q3 2025 Financial Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q3 2025 Financial Results Conference Call
Newswire.ca
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Newswire.ca
HLS Therapeutics Announces New Credit Agreement
Newswire.ca
HLS Therapeutics Announces Q2 2025 Financial Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q2 2025 Financial Results Conference Call
Newswire.ca
HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan
Newswire.ca
HLS Therapeutics Reports Annual Meeting Results
Newswire.ca
HLS Therapeutics Announces Q1 2025 Financial Results
Newswire.ca
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
Newswire.ca
HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q1 2025 Financial Results Conference Call
Newswire.ca
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid
Newswire.ca
HLS Therapeutics Appoints Christine Elliott to its Board of Directors
Newswire.ca
HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call
The Globe and Mail
Friday’s analyst upgrades and downgrades
Shoppers come and go from a Canadian Tire store in Ottawa on Friday, Aug. 11, 2023.
PR Newswire
HLS Therapeutics Announces Q3 2024 Financial Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call
PR Newswire
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call
Baystreet
Stocks in play: HLS Therapeutics Inc.

Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.